{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T03:56:50Z","timestamp":1769659010459,"version":"3.49.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2014,6,26]],"date-time":"2014-06-26T00:00:00Z","timestamp":1403740800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1038\/hr.2014.104","type":"journal-article","created":{"date-parts":[[2014,6,26]],"date-time":"2014-06-26T05:59:01Z","timestamp":1403762341000},"page":"950-953","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Long-term effect of antihypertensive drugs on the risk of new-onset atrial fibrillation: a longitudinal cohort study"],"prefix":"10.1038","volume":"37","author":[{"given":"Gwo-Ping","family":"Jong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hung-Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-sheng","family":"Liou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,6,26]]},"reference":[{"key":"BFhr2014104_CR1","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1291\/hypres.30.535","volume":"30","author":"MG Hennersdorf","year":"2007","unstructured":"Hennersdorf MG, Schueller PO, Strauer BE . Prevalence of paroxysmal atrial fibrillation depending on the regression of left ventricular hypertrophy in arterial hypertension. Hypertens Res 2007; 30: 535\u2013540.","journal-title":"Hypertens Res"},{"key":"BFhr2014104_CR2","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","volume":"22","author":"PA Wolf","year":"1991","unstructured":"Wolf PA, Abbott RD, Kannel WB . Atrial fibrillation as an independent risk for stroke: the Framingham Study. Stroke 1991; 22: 983\u2013988.","journal-title":"Stroke"},{"key":"BFhr2014104_CR3","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.jacc.2006.10.062","volume":"49","author":"Y Miyasaka","year":"2007","unstructured":"Miyasaka Y, Barnes ME, Elailey KR, Cha SS, Gersh BJ, Seward JB, Tsang TSM . Mortality trends in patients diagnosed with first atrial fibrillation: a 21-year community-base study. J Am Coll Cardiol 2007; 49: 986\u2013992.","journal-title":"J Am Coll Cardiol"},{"key":"BFhr2014104_CR4","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S0140-6736(98)05012-0","volume":"353","author":"L Hansson","year":"1999","unstructured":"Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanm\u00e4ki K, Dahl\u00f6f B, Faire U, M\u00f6rlin C, Karlberg BE, Wester PO, Bj\u00f6rck JE . Effect of angiotensin-converting- enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial. Lancet 1999; 353: 611\u2013616.","journal-title":"Lancet"},{"key":"BFhr2014104_CR5","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.jacc.2004.10.068","volume":"45","author":"K Wachtell","year":"2005","unstructured":"Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlo'f B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Devereux RB . Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005; 45: 712\u2013719.","journal-title":"J Am Coll Cardiol"},{"key":"BFhr2014104_CR6","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1016\/j.jacc.2004.11.070","volume":"45","author":"JS Healey","year":"2005","unstructured":"Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S, Connolly SJ . Prevention of atrial fibrillation with angiotensin- converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005; 45: 1832\u20131839.","journal-title":"J Am Coll Cardiol"},{"key":"BFhr2014104_CR7","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.ahj.2006.01.007","volume":"152","author":"K Anand","year":"2006","unstructured":"Anand K, Mooss AN, Hee TT, Mohiuddin SM . Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation. Am Heart J 2006; 152: 217\u2013222.","journal-title":"Am Heart J"},{"key":"BFhr2014104_CR8","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1093\/eurheartj\/ehl484","volume":"28","author":"IA Nasr","year":"2007","unstructured":"Nasr IA, Bouzamondo A, Hulot JS, Dubourg O, Le Heuzey JY, Lechat P . Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis. Eur Heart J 2007; 28: 457\u2013462.","journal-title":"Eur Heart J"},{"issue":"suppl H","key":"BFhr2014104_CR9","doi-asserted-by":"publisher","first-page":"H11","DOI":"10.1093\/eurheartj\/sun033","volume":"10","author":"P Dorian","year":"2008","unstructured":"Dorian P, Singh BN . Upstream therapies to prevent atrial fibrillation. Eur Heart J 2008; 10 (suppl H): H11\u2013H31.","journal-title":"Eur Heart J"},{"key":"BFhr2014104_CR10","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/ajh.2009.33","volume":"22","author":"SR Heckbert","year":"2009","unstructured":"Heckbert SR, Wiggins KL, Glazer NL, Dublin S, Psaty BM, Smith NL, Longstreth WT Jr, Lumley T . Antihypertensive treatment with ACE inhibitors or beta-blockers and risk of incident atrial fibrillation in a general hypertensive population. Am J Hypertens 2009; 22: 538\u2013544.","journal-title":"Am J Hypertens"},{"key":"BFhr2014104_CR11","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.ahj.2010.02.016","volume":"159","author":"M Disertori","year":"2010","unstructured":"Disertori M, Lombardi F, Barlera S, Latini R, Maggioni AP, Zeni P, Pasquale GD, Cosmi F, Franzosi MG . Clinical predictors of atrial fibrillation in the Gruppo Italiano per lo Studio della Sopravvivenza nell\u2019lnfarto Miocardico-Atrial Fibrillation\u2019 (GISSI-AF) trial. Am Heart J 2010; 159: 857\u2013863.","journal-title":"Am Heart J"},{"key":"BFhr2014104_CR12","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1136\/pgmj.62.734.1125","volume":"62","author":"MK Emara","year":"1986","unstructured":"Emara MK, Saadet AM . Transient atrial fibrillationin hypertensive patients with thiazide induced hypokalemia. Postgrad Med 1986; 62: 1125\u20131127.","journal-title":"Postgrad Med"},{"key":"BFhr2014104_CR13","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1046\/j.1540-8167.2001.00592.x","volume":"12","author":"P Schauerte","year":"2001","unstructured":"Schauerte P, Scherlag BJ, Patterson E, Scherlag MA, Matsudaria K, Nakagawa H, Lazzara R, Jackman WM . Focal atrial fibrillation: experimental evidence for a pathophysiologic role of the autonomic nervous system. J Cardiovasc Electrophysiol 2001; 12: 592\u2013599.","journal-title":"J Cardiovasc Electrophysiol"},{"key":"BFhr2014104_CR14","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1136\/bmj.326.7404.1427","volume":"326","author":"MR Law","year":"2003","unstructured":"Law MR, Wald NJ, Morris JK, Jordan RE . Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326: 1427\u20131435.","journal-title":"BMJ"},{"key":"BFhr2014104_CR15","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1590\/S1807-59322010000300005","volume":"65","author":"AE Pesaro","year":"2010","unstructured":"Pesaro AE, de Matos Soeiro A, Serrano CV, Giraldez RR, Ladeira RT, Nicolau JC . Effect of beta-blockers on the risk of atrial fibrillation in patients with acute myocardial infarction. Clinics (Sao Paulo) 2010; 65: 265\u2013270.","journal-title":"Clinics (Sao Paulo)"},{"key":"BFhr2014104_CR16","doi-asserted-by":"publisher","first-page":"e353","DOI":"10.3399\/bjgp11X578034","volume":"61","author":"JA Hodgkinson","year":"2011","unstructured":"Hodgkinson JA, Taylor CJ, Hobbs FDR . Predictors of incident atrial fibrillation and influence of medications: a retrospective case-control study. Br J Gen Pract 2011; 61: e353\u2013e361.","journal-title":"Br J Gen Pract"},{"key":"BFhr2014104_CR17","doi-asserted-by":"publisher","first-page":"78","DOI":"10.7326\/0003-4819-152-2-201001190-00005","volume":"152","author":"BA Schaer","year":"2010","unstructured":"Schaer BA, Schneider C, Jick SS, Conen D, Osswald S, Meier CR . Risk for incident atrial fibrillation in patients who receive antihypertensive drugs. Ann Intern Med 2010; 152: 78\u201384.","journal-title":"Ann Intern Med"},{"key":"BFhr2014104_CR18","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1161\/01.CIR.0000072793.81076.D4","volume":"107","author":"E Vermes","year":"2003","unstructured":"Vermes E, Tardif JC, Bourassa MG, Racine N, Levesque S, White M, Guerra PG, Ducharme A . Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003; 107: 2926\u20132931.","journal-title":"Circulation"},{"key":"BFhr2014104_CR19","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.ahj.2004.09.033","volume":"149","author":"AP Maggioni","year":"2005","unstructured":"Maggioni AP, Latini R, Carson PE, Singh SN, Barlera S, Glazer R, Glazer R, Masson S, Cer\u00e8 E, Tognoni G, Cohn JN, for the Val-HeFT Investigators. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005; 149: 548\u2013557.","journal-title":"Am Heart J"},{"key":"BFhr2014104_CR20","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ahj.2005.06.036","volume":"152","author":"A Ducharme","year":"2006","unstructured":"Ducharme A, Swedberg K, Pfeffer MA, Cohen-Solal A, Granger CB, Maggioni AP, Michelson EL, McMurray JJV, Olsson L, Rouleau JL, Young JB, Olofsson B, Puu M, Yusuf S, on behalf of the CHARM Investigators. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 2006; 152: 86\u201392.","journal-title":"Am Heart J"},{"key":"BFhr2014104_CR21","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2147\/VHRM.S1899","volume":"4","author":"C Cuspidi","year":"2008","unstructured":"Cuspidi C, Negri F, Zanchetti A . Angiotensin II receptor blockers and cardiovascular protection: focus on left ventricular hypertrophy regression and atrial fibrillation prevention. Vasc Health Risk Manag 2008; 4: 67\u201373.","journal-title":"Vasc Health Risk Manag"},{"key":"BFhr2014104_CR22","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jacc.2004.03.056","volume":"44","author":"PL L\u2019Allier","year":"2004","unstructured":"L\u2019Allier PL, Ducharme A, Keller PF, Yu H, Guertin MC, Tardif JC . Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation. J Am Coll Cardiol 2004; 44: 159\u2013164.","journal-title":"J Am Coll Cardiol"},{"key":"BFhr2014104_CR23","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1161\/STROKEAHA.110.589531","volume":"41","author":"AJS Webb","year":"2010","unstructured":"Webb AJS, Rothwell PM . Blood pressure variability and risk of new-onset atrial fibrillation: a systematic review of randomized trial of antihypertensive drugs. Stroke 2010; 41: 2091\u20132093.","journal-title":"Stroke"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/hr2014104.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/hr2014104","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/hr2014104.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T17:13:24Z","timestamp":1684430004000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/hr2014104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,26]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["BFhr2014104"],"URL":"https:\/\/doi.org\/10.1038\/hr.2014.104","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,26]]},"assertion":[{"value":"6 December 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All the authors report receiving lecture fees from various pharmaceutical companies in Taiwan.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}